TAK 100

Drug Profile

TAK 100

Alternative Names: TAK-100

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Takeda
  • Class Antihyperglycaemics
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 21 May 2010 Discontinued - Phase-I for Type-2 diabetes mellitus in Japan (PO)
  • 06 May 2010 TAK 100 is still in phase I trials for Type-2 diabetes in Japan
  • 31 Jan 2008 Phase-I clinical trials in Type-2 diabetes mellitus in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top